Voyager Therapeutics, a US clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, announced that it has entered into collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to further expand Voyager’s manufacturing capabilities to support the development of its gene therapy programs.
The collaborations allow Voyager to transfer its research and development production capabilities to a gene therapy contract development and manufacturing organizations (CDMO) with late-stage clinical and commercial-scale capabilities, particularly as it relates to the baculovirus/Sf9 system for manufacturing adeno-associated virus (AAV) gene therapies.
Voyager focuses on developing internal processes and capabilities to produce high-yield and high-quality gene therapies, including the use of the baculovirus/Sf9 AAV production system, with the potential to transfer these capabilities to increase capacity and scale through the use of external CDMOs. The company will partner with Brammer to implement a manufacturing process under current good manufacturing practice (cGMP) at their US facility in Cambridge. The partnership with Fujifilm to provide first-in-human cGMP clinical trial material production capacity.
Voyager Therapeutics was founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience. Its manufacturing platform utilizes a baculovirus/Sf9 cell production process that enables the production of AAV vectors at clinical and commercial scale, with the potential for increased yields over traditional production processes.